An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Clinical trial NCT02472145 · COMPLETED

Trial details

NCT number: NCT02472145
Sponsor: Janssen Research & Development, LLC
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Leukemia, Myeloid, Acute

Start date: 2015-08-04
Primary completion: 2018-01-25
Enrollment: 326

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.